Lactobacillus rhamnosus GG (LGG) for Antibiotic Associated Diarrhea
Verdict: Published with Warning
Across 6 PubMed studies, the evidence for Lactobacillus rhamnosus GG (LGG) in Antibiotic Associated Diarrhea grades Tier A — moderate evidence. Effective, but with safety or population caveats.
A 🔵 A Moderate Evidence Published with Warning
Why this grade7-layer evidence engine
⚖️
Scoring transparency
All scores computed by a 7-layer evidence engine — fully auditableRaw score 0.72
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
A · Published with Warning
Confidence
70%
Broadly consistent
Evidence level
E1
Cochrane high-quality SR/MA
▸View the full decision path (audit trail)
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.723
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 高品質 SR/MA 顯示 positive (3 篇 > 0 negative)
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
PubMed studies (6)L2 · primary research & systematic reviews
Probiotics for the prevention of pediatric antibiotic-associated diarrhea (Cochrane Review, Guo et al., update of CD004827.pub5)
Finding: Overall probiotics cut AAD from 19% to 8% (33 RCTs, RR 0.45, 95% CI 0.36-0.56, NNT 9); in the 6 LGG-specific trials AAD fell from 22% to 8% (RR 0.37, 95% CI 0.24-0.55), and high-dose (>=5 billion CFU/d) was more effective (RR 0.37) than low-dose (RR 0.68, CI 0.46-1.01).
View on PubMed Comparative efficacy and tolerability of probiotics for antibiotic-associated diarrhea: Systematic review with network meta-analysis (Cai et al.)
Finding: Across 51 RCTs (60 comparisons, 9569 participants), LGG had the highest probability of ranking best for both effectiveness (OR 0.28, 95% CI 0.17-0.47) and tolerability (OR 0.44, 95% CI 0.23-0.84) for AAD prevention, while L. casei ranked best specifically for C. difficile infection.
View on PubMed Systematic review with meta-analysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults (Szajewska & Kolodziej)
Finding: LGG reduced AAD from 22.4% to 12.3% overall (12 RCTs, RR 0.49, 95% CI 0.29-0.83); significant in children (RR 0.48, 95% CI 0.26-0.89, n=445) and in adults on H. pylori eradication (RR 0.26, 95% CI 0.11-0.59, n=280) but NOT significant in general adults (RR 0.48, 95% CI 0.20-1.15, n=863); evidence quality moderate-to-low.
View on PubMed Probiotics for the Prevention of Antibiotic-Associated Diarrhea in Outpatients - A Systematic Review and Meta-Analysis (Blaabjerg et al., Antibiotics Basel)
Finding: Across 17 RCTs (3631 outpatients) probiotics cut AAD from 17.7% to 8.0% (RR 0.49, 95% CI 0.36-0.66, I2=58%); in strain subgroups LGG was among the most effective (RR 0.29, 95% CI 0.15-0.57), comparable to S. boulardii (RR 0.41, 95% CI 0.30-0.57).
View on PubMed Meta-analysis of probiotics for the prevention of antibiotic associated diarrhea and the treatment of Clostridium difficile disease (McFarland)
Finding: Across 25 AAD RCTs (3164 subjects) probiotics significantly reduced AAD (RR 0.43, 95% CI 0.31-0.58, p<0.001); only S. boulardii, LGG, and probiotic mixtures showed significant benefit, but LGG was pooled at species/mixture level rather than as an isolated strain estimate here.
View on PubMed Is Lactobacillus rhamnosus GG effective in preventing the onset of antibiotic-associated diarrhoea: a systematic review (Hawrelak et al., Digestion)
Finding: Of 6 included trials, 4 found a significant reduction in AAD risk with LGG, 1 found reduced diarrhea duration, and 1 found no benefit; authors concluded LGG shows promise but more research is needed (narrative synthesis, no pooled effect size reported).
View on PubMed Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …
L4a US FDA
Supportive
GRN No. 231 — Notified Substance: Lactobacillus casei subsp. rhamnosus strain GG. Intended Use: Ingredient in term infant formula, at levels not to exceed 10^8 colony forming units per gram of powdered formula. Notifier: Mead Johnson & Company. Agency Response: FDA has no questions (closure date: May 29, 2008). source↗
L4b EU EFSA
Cautious
The bacterial species L. rhamnosus (now Lacticaseibacillus rhamnosus) is considered by EFSA to be suitable for the qualified presumption of safety (QPS) approach to safety assessment. However, the EFSA Panel on Dietetic Products, Nutrition and Allergies concluded that a cause and effect relationship has not been established between the consumption of Lactobacillus rhamnosus GG (ATCC 53103, LGG)… source↗
L4c UK NHS
Neutral
Probiotics are generally classed as food rather than medicine, which means they don't go through the rigorous testing medicines do. ... For most people, probiotics appear to be safe. If you want to try them, and you have a healthy immune system, they shouldn't cause any unpleasant side effects. ... If you have an existing health condition or a weakened immune system, you should talk to a doctor… source↗
L4d TW TFDA / 衛福部
Supportive
Lactobacillus rhamnosus is listed in the 'Food Ingredients Available for Use' (可供食品使用原料) comprehensive list as a lactic acid bacterium (乳酸菌), in the form of bacterial cells (菌體), and can be used as a food ingredient or for food processing purposes. source↗
L4e WHO
Supportive
Administration of Lacticaseibacillus rhamnosus GG (LGG) to children with gastroenteritis is recommended by universal guidelines. The World Gastroenterology Organisation's Global Guidelines for Probiotics and Prebiotics (2023 update) lists LGG as having documented, positive results in multiple gut-related health areas. The FAO/WHO Joint Working Group (London, Ontario, 2002) 'Guidelines for the E… source↗
L5a NIH Office of Dietary Supplements
Supportive
Lactobacillus rhamnosus GG is an example where Lactobacillus is the genus, rhamnosus is the species, and GG is the strain. Treatment with LGG compared with placebo or no additional treatment reduced the risk of antibiotic-associated diarrhea in patients treated with antibiotics from 22.4% to 12.3% (relative risk: 0.49). However, when children and adults were evaluated separately, the difference… source↗
L5b Mayo Clinic
Cautious
A person might have a reduced chance of having diarrhea related to taking antibiotics, called antibiotic-associated diarrhea, when taking acidophilus along with other specific forms of lactobacillus. It also might lessen diarrhea, bloating and cramps... However, more research needs to be done. source↗
L5c Cleveland Clinic
Supportive
The thing that has really been shown to help the most with preventing diarrhea is taking probiotics when taking antibiotics. ... reviews of studies suggest probiotics are effective both for regular antibiotic-associated diarrhea and for diarrhea related to C. diff. ... The most commonly studied for antibiotic-associated diarrhea are Lactobacillus rhamnosus-based and Saccharomyces boulardii-base… source↗
L5d Harvard Health
Supportive
Those who took antibiotics plus probiotics were 42% less likely to develop diarrhea as those who got the placebo. source↗
L5e Specialty Society (condition-mapped)
Cautious
Probiotics and prebiotics for treatment are considered (not recommended). source↗